Key result
In canine isolated heart preparations, ONO-1101 acted as an ultrashort-acting beta-blocker with potency similar to or slightly greater than esmolol and a dose-dependent recovery time.
ONO-1101 is an ultrashort-acting beta-blocker with a dose-dependent recovery time and potency similar to or slightly greater than esmolol in canine heart preparations.
No takes yet. Share an insight, caveat, or question.
ONO-1101 shows no basal effects in canine SAN/PM preparations; hypothesis-generating for cardioselective beta-blockade pending in vivo data.
Motomura et al. (1998) studied this question. ONO-1101 vs. Esmolol and propranolol was evaluated on Maximal percentage inhibition of norepinephrine-induced increases in sinoatrial rate and papillary muscle developed tension. In canine isolated heart preparations, ONO-1101 acted as an ultrashort-acting beta-blocker with potency similar to or slightly greater than esmolol and a dose-dependent recovery time.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: